Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?

Area of Science:

• Immunology
• Neurology
• Infectious Diseases

Background:

• Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMO-SD) patients often receive immunosuppressive therapies.
• The impact of these treatments on long-term immune response to SARS-CoV-2 infection remains unclear.
• Understanding COVID-19's effect on immunocompromised individuals is crucial for patient management.

Discussion:

• This study investigated the serological response to COVID-19 in patients with MS and NMO-SD undergoing immunosuppressive treatment.
• A key focus was evaluating the efficacy of anti-CD20 therapies in modulating the immune response to SARS-CoV-2.
• The findings highlight potential long-term immunological consequences in this vulnerable patient population.

Key Insights:

• Among 13 MS or NMOSD patients with confirmed COVID-19, all 5 treated with anti-CD20 therapies showed negative SARS-CoV-2 serology.
• This suggests that anti-CD20 therapies may significantly impair the development of a detectable humoral immune response post-infection.
• The results underscore the importance of monitoring immune status in these patients.

Outlook:

• Further research is needed to explore the mechanisms behind impaired seroconversion in patients on anti-CD20 therapy.
• Long-term follow-up studies are essential to assess the clinical implications of absent or weak antibody responses.
• Recommendations for continued infection prevention strategies in MS/NMOSD patients, especially those on anti-CD20, are warranted.